SEBI Reg. Investment Advisor

Download App

Help Center Pricing

Recent:

Top Pharma Companies in India by Market Cap

BSE Sensex 77802.56
155.96 (-0.20%)

Filter

Top Pharma Companies in India as on May-2026 | 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks

Filter

	Company Name	DeciZen	Market cap (Rs. Cr.)	CMP (Change %)	Latest P/E	Latest P/BV	5Y Sales Gr.(%)	5Y Profit Gr.(%)
91	Unichem Laboratories Ltd.	Q V PT	2,726 Small Cap	391.40 (1.10%)	12.08	1.03	13.92	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
92	Hikal Ltd.	Q V+ PT	2,609 Small Cap	210.65 (-0.45%)	N/A	2.2	4.29	-1.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
93	Novartis India Ltd.	Q V+ PT	2,594 Small Cap	1,053 (0.22%)	26.68	3.28	-4.06	54.56	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
94	Fischer Medical Ventures Ltd.	Q V PT	2,506 Small Cap	38.53 (0.63%)	N/A	7.79	96.10	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
95	Solara Active Pharma Sciences Ltd.	Q V PT	2,473 Small Cap	528.15 (2.89%)	N/A	1.99	-0.58	-134.64	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
96	Dr Agarwals Eye Hospital Ltd.	Q V PT	2,470 Small Cap	5,172.70 (1.23%)	35.36	7.44	17.68	31.54	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
97	Panacea Biotec Ltd.	Q V+ PT	2,442 Small Cap	406.25 (1.88%)	N/A	8.59	-8.75	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
98	Morepen Laboratories Ltd.	Q V+ PT	2,387 Small Cap	43.75 (0.44%)	41.26	1.96	14.44	19.03	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
99	Vimta Labs Ltd.	Q V+ PT	2,282 Small Cap	540.35 (5.77%)	29.44	5.26	13.74	62.65	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
100	Indoco Remedies Ltd.	Q V+ PT	2,104 Small Cap	227.45 (-0.22%)	N/A	1.97	6.54	-182.78	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
101	Krsnaa Diagnostics Ltd.	Q V PT	1,979 Small Cap	606.50 (-0.59%)	24.62	2.11	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
102	Windlas Biotech Ltd.	Q V PT	1,822 Small Cap	864.55 (0.16%)	27.31	3.32	18.24	17.22	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
103	Shalby Ltd.	Q V PT	1,796 Small Cap	168.35 (1.23%)	24.21	1.5	12.52	25.39	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
104	Kwality Pharmaceuticals Ltd.	Q V+ PT	1,791 Small Cap	1,713.70 (-0.71%)	31.67	5.83	21.70	37.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
105	Suraksha Diagnostic Ltd.	Q V PT	1,462 Small Cap	283.45 (0.96%)	43.92	6.15	9.86	-51.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
106	KMC Speciality Hospitals (India) Ltd.	Q V PT	1,412 Small Cap	89 (2.78%)	N/A	N/A	19.21	12.72	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
107	Hester Biosciences Ltd.	Q V+ PT	1,409 Small Cap	1,642.20 (-0.85%)	39.86	3.93	11.08	0.75	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
108	Jagsonpal Pharmaceuticals Ltd.	Q V+ PT	1,407 Small Cap	209.35 (-0.07%)	32.65	5.09	11.13	39.15	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
109	Syncom Formulations (India) Ltd.	Q V PT	1,351 Small Cap	14.54 (1.18%)	19.59	3.42	17.63	21.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
110	Lincoln Pharmaceuticals Ltd.	Q V PT	1,347 Small Cap	672.65 (0.06%)	15.33	1.81	10.63	11.62	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
111	Tarsons Products Ltd.	Q V+ PT	1,214 Small Cap	231.15 (1.34%)	36.87	1.81	12.30	-1.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
112	Laxmi Dental Ltd.	Q V PT	1,177 Small Cap	212.50 (-0.79%)	91.24	4.96	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
113	GPT Healthcare Ltd.	Q V PT	1,154 Small Cap	142 (1.00%)	28.46	4.38	13.96	24.04	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
114	3B Blackbio Dx Ltd.	Q V PT	1,129 Small Cap	1,300.05 (-1.21%)	22.1	3.63	46.29	132.12	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
115	Bajaj Healthcare Ltd.	Q V PT	1,128 Small Cap	343.65 (2.52%)	21.57	1.97	5.76	2.91	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
116	Gujarat Kidney And Super Speciality Ltd.	Q V+ PT	973 Small Cap	126.75 (2.67%)	669.59	N/A	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
117	Themis Medicare Ltd.	Q V PT	916 Small Cap	98.36 (-1.15%)	N/A	3.06	15.00	7.68	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
118	Health X Platform Ltd.	Q V PT	907 Small Cap	285 (0.00%)	N/A	3.35	109.13	-201.92	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
119	Wanbury Ltd.	Q V+ PT	901 Small Cap	255.80 (-0.78%)	13.92	7.32	10.29	30.27	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
120	Fermenta Biotech Ltd.	Q V PT	887 Small Cap	303 (0.56%)	12.31	2.14	7.46	0.93	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
Prev 1 2 3 4 5 Next

Screens:

AlphaCases Top Rated Stocks Best Nifty Stocks Best Nifty Next Stocks Best Nifty 500 Stocks Best SmallCap Stocks Top BFSI Stocks

Pharma - Today's Top Gainers

Company Name	CMP	Price Change(%)
Piramal Pharma	188.75	14.32%
Vimta Labs	540.35	5.77%
Sun Pharma Adv. Res	165.45	5.35%
Guj. Themis Biosyn	396.30	4.68%
Nectar Lifesciences	12.80	3.56%

Pharma - Today's Top Losers

Company Name	CMP	Price Change(%)
Wockhardt	1,642.10	-4.54%
Concord Biotech	1,199	-1.97%
Rubicon Research	980.85	-1.83%
Innova Captab	862.40	-1.50%
Dr. Agarwals Health	451.30	-1.50%

News about Top Pharma Companies in India

May, 2026

Vimta Labs - Quaterly Results

The revenue zoomed 15.68% to Rs. 1092.45 millions for the quarter ended March 2026 as compared to Rs. 944.41 millions during the corresponding quarter last year.A humble growth in net profit of 15.25% reported in the quarter ended March 2026 to Rs. 211.13 millions from Rs. 183.19 millions.Operating profit for the quarter ended March 2026 rose to 421.19 millions as compared to 346.77 millions of corresponding quarter ended March 2025.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202603	202503	% Var	202603	202503	% Var	202603	202503	% Var
Sales	1092.45	944.41	15.68	4072.90	3439.82	18.40	4072.90	3439.82	18.40
Other Income	27.51	16.40	67.74	89.89	42.40	112.00	89.89	42.40	112.00
PBIDT	421.19	346.77	21.46	1505.08	1261.89	19.27	1505.08	1261.89	19.27
Interest	3.21	4.38	-26.71	11.67	19.00	-38.58	11.67	19.00	-38.58
PBDT	417.98	342.39	22.08	1477.25	1242.89	18.86	1477.25	1242.89	18.86
Depreciation	127.51	92.12	38.42	437.72	352.89	24.04	437.72	352.89	24.04
PBT	290.47	250.27	16.06	1039.53	890.00	16.80	1039.53	890.00	16.80
TAX	79.34	67.08	18.28	264.41	222.45	18.86	264.41	222.45	18.86
Deferred Tax	16.91	-2.58	-755.43	-1.07	12.66	-108.45	-1.07	12.66	-108.45
PAT	211.13	183.19	15.25	775.12	667.55	16.11	775.12	667.55	16.11
Equity	89.34	44.47	100.90	89.34	44.47	100.90	89.34	44.47	100.90
PBIDTM(%)	38.55	36.72	5.00	36.95	36.68	0.73	36.95	36.68	0.73

May, 2026

Bajaj Healthcare submits board meeting intimation

Bajaj Healthcare has informed that the meeting of the Board of Directors of the Company is scheduled on 08/05/2026, to consider and approve Audited Financial Results of the Company for the quarter and financial year ended March 31, 2026; and recommend Final Dividend on Equity Shares if any, for the Financial Year 2025-26 subject to the approval of Shareholders of the Company at the ensuing Annual General Meeting of the Company.

The above information is a part of company’s filings submitted to BSE.

Apr, 2026

Panacea Biotec informs about disclosure

Pursuant to Regulation 30 read with Para B of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR Regulations), Panacea Biotec has informed that the Income Tax Appellate Tribunal (ITAT) vide its Order dated April 29, 2026, allowed the appeal filed by the Company and set aside the Order dated August 14, 2025 of Commissioner of Income Tax (Appeals) (CIT(A)) arising out of Rectified Assessment Order dated October 10, 2023 passed earlier by Assessing Officer u/s 143(3) read with section 154 of the Income Tax Act, 1961 (Act). As per the aforesaid Rectified Assessment Order dated October 10, 2023, the Assessing Officer raised a demand of ?9.16 Crore for Assessment Year 2020-21 on account of addition of ?3.44 Crore under Section 14A of the Act read with Rule 8D of the Income Tax Rules, 1962. The aforesaid ITAT Order effectively results in deletion of the said disallowances of expenses as well as cancellation of demand of ?9.16 Crore previously raised by Assessing Officer for the Assessment Year 2020- 21. The requisite details as required under Regulation 30 of the SEBI LODR Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, and Industry Standards on Regulation 30 of SEBI LODR Regulations, are annexed as Annexure A.

The above information is a part of company’s filings submitted to BSE.

Apr, 2026

Wanbury rises as its Patalganga facility completes MFDS inspection successfully

Inspection completed with no observation (Zero Observation) confirming cGMP compliance per international rules

Apr, 2026

Wanbury’s Patalganga facility completes MFDS inspection successfully

Inspection completed with no observation (Zero Observation) confirming cGMP compliance per international rules

Apr, 2026

USFDA issues EIR with VAI classification to Solara Active Pharma Sciences’ Puducherry facility

The unannounced inspection was carried out by the US Food and Drug Administration between February 02, 2026 to February 6, 2026

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Rank	Company	Market Capitalization 2026 (INR crores)
1	Sun Pharmaceutical Industries Ltd.	4,43,973 Crore
2	Divis Laboratories Ltd.	1,78,026 Crore
3	Torrent Pharmaceuticals Ltd.	1,47,478 Crore
4	Lupin Ltd.	1,11,668 Crore
5	Apollo Hospitals Enterprise Ltd.	1,11,527 Crore
6	Cipla Ltd.	1,10,283 Crore
7	Dr. Reddys Laboratories Ltd.	1,09,382 Crore
8	Max Healthcare Institute Ltd.	98,852 Crore
9	Mankind Pharma Ltd.	97,506 Crore
10	Zydus Lifesciences Ltd.	94,495 Crore

Do you know? Asking 3 Right Questions minimizes the RISK of Stock Investing To Know

Right Stock | Right Price | Right Allocation

Find best stocks to buy now Find best pharma stocks to buy now

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

You can use different criterias to arrive at the list of best stocks in the Nifty Pharma company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Pharma companies index are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	ROE
Abbott India Ltd. (M)	Very Good	26,732	55,876	36.66	12.74	25.65	35.71
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,377	1,47,478	64.91	16.23	36.68	26.68
Ajanta Pharma Ltd. (S)	Very Good	3,097	38,646	36.60	8.54	24.73	24.45
Lupin Ltd. (M)	Somewhat Good	2,465	1,11,668	24.04	5.37	14.31	20.83
Zydus Lifesciences Ltd. (M)	Very Good	938	94,495	19.13	3.60	11.92	20.74

Based on the past year's gain, the best performing stocks are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	Yearly gain (%)
Laurus Labs Ltd. (M)	Very Good	1,207	63,517	92.14
Glenmark Pharmaceuticals Ltd. (M)	Very Good	2,373	66,987	68.93
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,152	34,370	42.38
Wockhardt Ltd. (S)	Not Good	1,642	27,953	39.71
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,377	1,47,478	33.30
				View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Sales Growth (%)
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,152	34,370	47.25	8.81	29.84	17.81
Mankind Pharma Ltd. (M)	Very Good	2,354	97,506	57.24	6.11	34.36	14.65
Laurus Labs Ltd. (M)	Very Good	1,207	63,517	71.46	11.98	35.90	14.42
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,308	1,09,382	19.64	2.94	11.80	13.26
Ajanta Pharma Ltd. (S)	Very Good	3,097	38,646	36.60	8.54	24.73	12.43

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Profit Growth (%)
Zydus Lifesciences Ltd. (M)	Very Good	938	94,495	19.13	3.60	11.92	30.57
Cipla Ltd. (L)	Very Good	1,367	1,10,283	24.26	3.28	14.63	30.14
Sun Pharmaceutical Industries Ltd. (L)	Very Good	1,833	4,43,973	40.67	5.47	22.24	23.50
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,308	1,09,382	19.64	2.94	11.80	22.29
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,152	34,370	47.25	8.81	29.84	19.45

You have 0 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Top Pharma Companies in India by Market Cap

News about Top Pharma Companies in India

Vimta Labs - Quaterly Results

Bajaj Healthcare submits board meeting intimation

Panacea Biotec informs about disclosure

Wanbury rises as its Patalganga facility completes MFDS inspection successfully

Wanbury’s Patalganga facility completes MFDS inspection successfully

USFDA issues EIR with VAI classification to Solara Active Pharma Sciences’ Puducherry facility

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

How to select the top Nifty Pharma stocks based on RoE?

What are the best-performing stocks in the Nifty Pharma index?

Which Nifty Pharma stocks have the highest revenue growth in the past five years?

Which Nifty Pharma stocks had the highest profit growth in the past five years ?

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.